hide-icon
Banner

In this Association for Molecular Pathology (AMP) session, Professor Metzeler describes the current technology landscape and prognostic relevance of minimal residual disease (MRD) detection and demonstrates his experience using NGS-based MRD detection in acute myeloid leukemia (AML), including OGT’s NGS-based SureSeq™ Myeloid MRD Panel.

The results of the study showed that the SureSeq Myeloid MRD Panel:

  • Detected 100% of covered variants, with no apparent false-positive calls
  • Delivered high coverage uniformity and low background noise, resulting in high sensitivity
  • Found several additional clinically relevant variants, including FLT3-ITD mutations
  • Allowed for a flexible panel design, which will allow for future modifications to cover additional genes and exons

The results from the study show the potential application of the SureSeq Myeloid MRD Panel as a tool for further investigation of MRD in AML samples.

Share your details to gain access

  • Share